SSY Group Ltd
HKEX:2005
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.3
5.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
SSY Group Ltd
Long-Term Debt
SSY Group Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SSY Group Ltd
HKEX:2005
|
Long-Term Debt
HK$2.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Long-Term Debt
HK$2.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
28%
|
CAGR 10-Years
27%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Long-Term Debt
¥1.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-2%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Long-Term Debt
¥1.2B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
1%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Long-Term Debt
HK$21.7B
|
CAGR 3-Years
58%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Long-Term Debt
$55.6m
|
CAGR 3-Years
111%
|
CAGR 5-Years
72%
|
CAGR 10-Years
8%
|
|
SSY Group Ltd
Glance View
SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.
See Also
What is SSY Group Ltd's Long-Term Debt?
Long-Term Debt
2.7B
HKD
Based on the financial report for Jun 30, 2024, SSY Group Ltd's Long-Term Debt amounts to 2.7B HKD.
What is SSY Group Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
15%
Over the last year, the Long-Term Debt growth was 58%. The average annual Long-Term Debt growth rates for SSY Group Ltd have been 27% over the past three years , 24% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet
